Literature DB >> 22537437

New virologic tools for management of chronic hepatitis B and C.

Stéphane Chevaliez1, Christophe Rodriguez, Jean-Michel Pawlotsky.   

Abstract

Molecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze their sequence to determine their genotype or subtype and to identify nucleotide or amino acid substitutions associated with resistance to antiviral drugs. They include real-time target amplification methods, which have been standardized and are widely used in clinical practice to diagnose and monitor HBV and HCV infections, and next-generation sequencing techniques, which are still restricted to research laboratories. In addition, new enzyme immunoassays can quantify hepatitis B surface and hepatitis C core antigens, and point-of-care tests and alternatives to biologic tests that require whole-blood samples obtained by venipuncture have been developed. We review these new virologic methods and their clinical and research applications to HBV and HCV infections.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537437      PMCID: PMC3477068          DOI: 10.1053/j.gastro.2012.02.027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  71 in total

1.  Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Syria Laperche; Christophe Hézode; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

3.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

Review 4.  Host genomics and HCV treatment response.

Authors:  Paul J Clark; Alexander J Thompson
Journal:  J Gastroenterol Hepatol       Date:  2012-02       Impact factor: 4.029

Review 5.  Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 6.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

7.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

9.  Evaluation of next generation sequencing platforms for population targeted sequencing studies.

Authors:  Olivier Harismendy; Pauline C Ng; Robert L Strausberg; Xiaoyun Wang; Timothy B Stockwell; Karen Y Beeson; Nicholas J Schork; Sarah S Murray; Eric J Topol; Samuel Levy; Kelly A Frazer
Journal:  Genome Biol       Date:  2009-03-27       Impact factor: 13.583

10.  Substantial biases in ultra-short read data sets from high-throughput DNA sequencing.

Authors:  Juliane C Dohm; Claudio Lottaz; Tatiana Borodina; Heinz Himmelbauer
Journal:  Nucleic Acids Res       Date:  2008-07-26       Impact factor: 16.971

View more
  46 in total

1.  Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Authors:  Cédric Laouénan; Patrick Marcellin; Martine Lapalus; Feryel Khelifa-Mouri; Nathalie Boyer; Fabien Zoulim; Lawrence Serfaty; Jean-Pierre Bronowicki; Michelle Martinot-Peignoux; Olivier Lada; Tarik Asselah; Céline Dorival; Christophe Hézode; Fabrice Carrat; Florence Nicot; Gilles Peytavin; France Mentré; Jeremie Guedj
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Evaluation of dried blood spot as an alternative sample collection method for hepatitis C virus RNA quantitation and genotyping using a commercial system.

Authors:  Supriya Mahajan; Manish Chandra Choudhary; Guresh Kumar; Ekta Gupta
Journal:  Virusdisease       Date:  2018-03-21

3.  Point: is the era of viral culture over in the clinical microbiology laboratory?

Authors:  Richard L Hodinka
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

4.  Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.

Authors:  Widya Wasityastuti; Yoshihiko Yano; Dewiyani Indah Widasari; Laura Navika Yamani; Neneng Ratnasari; Didik Setyo Heriyanto; Rina Okada; Toshihito Tanahashi; Yoshiki Murakami; Takeshi Azuma; Yoshitake Hayashi
Journal:  Kobe J Med Sci       Date:  2016-06-16

5.  Alternative applications for distinct RNA sequencing strategies.

Authors:  Leng Han; Kasey C Vickers; David C Samuels; Yan Guo
Journal:  Brief Bioinform       Date:  2014-09-22       Impact factor: 11.622

Review 6.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 7.  Recent advances in micro/nanotechnologies for global control of hepatitis B infection.

Authors:  U Hakan Yildiz; Fatih Inci; ShuQi Wang; Mehlika Toy; H Cumhur Tekin; Asad Javaid; Daryl T-Y Lau; Utkan Demirci
Journal:  Biotechnol Adv       Date:  2014-11-20       Impact factor: 14.227

8.  The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Christophe Rodriguez; Alexandre Soulier; Jean-Dominique Poveda; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

Review 9.  Rapid and quantitative detection of hepatitis B virus.

Authors:  Yue-Ping Liu; Chun-Yan Yao
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 10.  Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?

Authors:  Jean-Michel Pawlotsky
Journal:  Curr Gastroenterol Rep       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.